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Diastereoselective Synthesis of b-Piperonyl-g-Butyrolactones from Morita-Baylis-Hillman 
Adducts. Highly Efficient Synthesis of (±)-Yatein, (±)-Podorhizol and (±)-epi-Podorhizol
Giordano Trazzi, Marcelo Fabiano André and Fernando Coelho*
Instituto de Química, Universidade Estadual de Campinas, CP 6154,  
13083-970 Campinas-SP, Brazil
Descrevemos nesse trabalho um método simples e eficiente para a preparação diastereosseletiva 
de b-piperonil-g-butirolactonas hidroxiladas, a partir de um aduto de Morita-Baylis-Hillman. 
Para exemplificar a eficiência dessa abordagem descrevemos também as sínteses das lignanas 
biologicamente ativas, (±)-yateína, (±)-podorizol e (±)-epi-podorizol.
Starting from a Morita-Baylis-Hillman adduct we describe a simple and very efficient method 
for the diastereoselective preparation of hydroxylated b-piperonyl-g-butyrolactones. To exemplify 
the efficiency of this approach we also describe a highly efficient synthesis for the biologically 
active lignans (±)-yatein, (±)-podorhizol and (±)-epi-podorhizol.
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Introduction
Lignans are natural products originated from a coupling 
reaction between C6-C3 units (phenylpropionate). These 
secondary metabolites are widely encountered in plant 
kingdom and present a huge structural diversity normally 
associated with interesting biological effects, such as anti-
tumoral, fungicide and anti-viral.1,2 Furthermore, they also 
show other biological activities against insects and some 
vertebrates (Figure 1).3
Trachelogenin amide A (1, Figure 1) is a dibenzyl-
butane lignan, isolated from the leaves and stems of 
Trachelospermum jasminoides. This plant is used in chinese 
folk medicine to treat rheumatic arthralgia, aching of 
loins and knees, and traumatic injuries.4 Actaelactone (2, 
Figure 1), is a dibenzylbutyrolactone lignan isolated from 
back cohosh (Actaea racemosa).5 Actaealactone showed 
antioxidant activity in the 1,1-diphenyl-2-picrylhydrazyl 
(DPPH) free-radical assay, with an IC50 value of 26 µmol L-1. 
It also exhibited a small stimulating effect on the growth 
of MCF-7 breast cancer cells. 9a-Angloyloxypinoresinol 
(3) has displayed inhibitory activity against HIV reverse 
transcriptase and was isolated from the roots and 
rhizomes of the chinese plant Ligularia kanaitizensis.6,7 
Kadsuralignan J (4) was isolated from roots of the chinese 
plant Kadsura coccinea and presents a moderate nitric 
oxide inhibitory activity.8 Beilschmin A (5) was isolated 
from the stems of chinese plant Beilschmiedia tsangii. This 
lignan was found to exhibit significant in vitro cytotoxicity 
against P-388 and HT-29 cell lines, with IC50 values of 
1.2 and 5.0 mg mL-1, respectively.9 The most prominent 
member of the aryltetralin lignan class is podophyllotoxin 
(6). This compound and some analogues have been isolated 
from American Mayapple (Podophyllum peltatum).10 
Podophyllotoxin (6) has long been known to possess anti-
mitotic activity with early clinical trials showing it to be 
highly efficacious but also quite toxic. Driven by the desire 
to enhance this biological profile, there have been many 
synthetic modifications to the podophyllotoxin structure, 
including the generation of potent anticancer agents. It is 
possible to include the following agents, as the actually 
marketed medicines Etoposide and Teniposide.10
The structural diversity and complexity associated with 
biological effects exhibit by lignans have stimulated the 
development of several synthetic approaches to prepare 
them, both in racemic and enantiomeric pure forms.11 Most 
of the synthetic methodologies are based on a b-aryl-g-
butyrolactone. This key intermediate is very important in 
the synthesis of butyrolactone lignans, which are used as 
plataform for the preparation of other lignans.12
Some years ago, Enders et al.13 elegantly demonstrated 
that hydroxylated b-aryl-g-butyrolactone is a central 
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Figure 1. Types and examples of biological active lignans.
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intermediate from which several different types of lignans 
can be synthesized (Figure 2).13,14
Results and Discussion
Morita-Baylis-Hillman is an amazing chemical 
transformation capable of efficiently providing highly 
Figure 2. b-Aryl-g-butyrolactone as key intermediates for lignans synthesis.
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functionalized b-hydroxy-a-methylene carbonyl 
derivatives.15,16 The adducts formed in this reaction have 
been used as substrate for the synthesis of natural products 
and drugs.17
Some years ago we reported, for the first time, a 
strategy which allowed the preparation of b-aryl-g-
butyrolactone using Morita-Baylis-Hillman adduct as 
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intermediates.14 This simple and straightforward strategy 
provided access to syn- and anti-hydroxylated b-aryl-g-
butyrolactone (8 and 9, respectively) in good yield. The 
diastereoselectivity for the syn isomer was acceptable 
(4:1), but for the anti was very poor (1:1.5). In this 
case, the presence of regioisomeric lactone 10 was also 
detected, thus compromising the whole efficiency of the 
synthetic methodology (Scheme 1).
Basically, a diastereoselective Michael addition of a 
cyanide to the double bond of a Morita-Baylis-Hillman 
gave 7a/b, as a mixture of diastereoisomers. Reduction 
of the ester group followed by basic hydrolysis of the 
nitrile group and in situ cyclisation, afford the desired 
butyrolactones in good yield. Unfortunately, this strategy 
had two major drawbacks. The first one was concerning 
the poor diastereoselectivity observed for the anti 
isomer. This isomer is particularly important for the 
synthesis of aryltetralin lactones, such as podophillotoxin. 
Second, an undesired regioisomeric butyrolactone (10) is 
formed, which renders the chromatographic separation 
laborious.
With the aim of overcoming afore mentioned drawbacks, 
we describe herein an alternative diastereoselective 
approach for the preparation of syn- and anti-hydroxylated 
b-aryl-g-butyrolactone. To demonstrate the versatility of our 
aproach we also describe a highly efficient total synthesis of 
(±)-yatein (11), (±)-podorhizol (12) and (±)-epi-podorhizol 
(13) (Figure 3).
Yatein (11) is a biologically active butyrolactone lignan. 
This natural compound has strong insect feeding deterrent,18 
and anti-viral activity.19 Podorhizol (12) presents a moderate 
anti-tumor activity,20 while epi-podorhizol (13) shows 
antibacterial activity.21
Hydroxylated b-aryl-g-butyrolactones can be prepared 
from a Morita-Baylis-Hillman using the synthetic strategy 
depicted in scheme below (Scheme 2).
The butyrolactones can be prepared by direct oxidation of 
lactol 14, which in turn can be synthesized in one step from 
cyanide-ester 7, using reductive conditions. The preparation 
of 7 can be secured by a diastereoselective Michael addition 
reaction with a suitable Morita-Baylis-Hillman adduct, such 
as 16. Based on our previous results, we anticipated good 
diastereoselective control could be achieved in the Michael 
step, mainly in the preparation of the syn diastereoisomer.14
In order to improve the diastereoselectivity in the 
preparation of anti isomer, we thought that b-ketoesters 15 
Scheme 1. Butyrolactones from Morita-Baylis-Hillman adducts.
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Figure 3. Lignans from a Morita-Baylis-Hillman addduct.
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Scheme 2. Retrosynthetic approach for the preparation of hydroxylated butyrolactones from Morita-Baylis-Hillman adduct.
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could be used as substrate in a diastereoselective reduction 
step. Based on a careful conformational analysis of 15, 
we likely assume that A is the most stable conformer 
(Scheme 3). We can thus expect that hydride attack should 
preferentially occur on the less hindered side, leading to 
the anti diastereoisomer as the major product. 
Taking in to account these preliminary considerations, 
we commenced with the synthesis of b-hydroxy-ester 16 
by coupling of methyl acrylate with piperonal. Electron-
rich aldehyde piperonal is very resistant to Morita-Baylis-
Hillman reaction and normally rate, conversion and yield 
are very low. Searching to circumvent this problem we 
carried out a reaction using an excess of acrylate (30 equiv.) 
in the presence of catalytic amount of an ionic liquid 
[bmim]PF6 (1-butyl-3-methylimidazolium hexafluoro-
phosphate) and ultrasound. Under these conditions, adduct 
16 was obtained after 80 h, in 89% yield (Scheme 4).
Michael addition reaction between sodium cyanide 
and adduct 16 afforded 7 in 87% yield but in a poor 
diastereoisomeric ratio (syn:anti; 1:1.5), as previously 
observed (Scheme 4).
The mixture was easily characterized by measuring the 
coupling constant (J) of the carbinolic proton in 1H NMR 
spectrum. A doublet resonance at 5.10 ppm (J 4.4 Hz) 
was attributed to the syn diastereomer, while the doublet 
resonance at 4.95 ppm (J 7.6 Hz) was attributed to the 
anti isomer. The spectral data are consistent with those 
previously reported in literature.14
The preparation of b-ketoester 15 was unexpectedly 
troublesome. We tested several different oxidizing reagents. 
The results are summarized in Table 1.
Depending on experimental conditions used the 
b-ketoester 15 was contaminated with the decarboxylation 
product 17 (entries 1 and 2, Table 1). It is known that 
hypervalent reagent can hydrolyse esters and acetals.23 
Then, we believe that the large excess of 2-iodoxybenzoic 
acid (IBX) used in the reaction has favored the hydrolysis of 
our keto ester, which subsequently loss CO2. The best result 
was achieved when Jones reagent was used in acetone at 
0 °C.24 Under these conditions, b-ketoester 15 was obtained 
as a sole product in 94% yield (entry 6, Table 1).
Having ketoester 15 in our hands, we subjected it to 
a set of different reductive conditions. The results are 
summarized in Table 2. 
In all cases, diastereoselectivity was better than that 
achieved by conjugate addition of cyanide to the double 
bond of Morita-Baylis-Hillman adduct. Moreover, 
the highest selectivity was attained when employing 
NaBH4 at room temperature and using methanol as 
solvent (syn:anti;1:10). The difference between the 
diastereoselectivity for the oxidation-reduction approach 
and the Michael addition of sodium cyanide Michael 
addition is remarkable (Figure 4). After a simple 
chromatographic purification, anti-(±)-7b was obtained 
as a sole diastereoisomer in 75% yield. To accomplish 
our goal, it was necessary to protect the secondary 
Scheme 3. Stereochemical racionalization to obtain anti isomer 7.
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Scheme 4. Preparation of cyanide 7. Reagents and conditions: (a) methyl acrylate (30 equiv.), DABCO, [bmim]PF6, ultrasound, 80 h, 89%; (b) NaCN, 
NH4Cl, DMF:H2O (3:1), 12 h, 87%.
Table 1. Preparation of b-keto ester 15
Ar O
OOH
CN
[O]
Ar O
OO
CN7a/b 15
+ Ar
O
17
Ar= 3,4-Methylenedioxyphenyl
CN
Entry Reaction conditions time Products, (%)a,b
1 IBX/CH3CN (reflux)c 12 h  15 + 17, 55
2 IBX (3 equiv.)/AcOEt (reflux) 12 h  15 + 17, 40
3 IBX (1.2 equiv.)/AcOEt (reflux) 12 h  15, 55
4 IBX (1.2 equiv.)/acetone 12 h  15, 45
5 PDC/CH2Cl2, r.t. 8 h 15, 65
6 CrO3-H2SO4/acetone, 0 °C 15-20 min 15, 94
a
 Yields refer to isolated and purified products; b all spectral data (1H NMR, 
13C NMR, IR, HRMS) are compatible with the proposed structures; c see 
reference 22.
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Table 2. Diastereoselective reduction of b-keto ester 17
Ar
O
O
O
CN
(±)-15
Ar= 3,4-Methylenedioxyphenyl
[H]
Ar
OH
O
O
CN
Ar
OH
O
O
CN
+
(syn)-±-7a (anti)-±-7b
Entry  Reaction conditions time (h) Products, %a,b 
syn:anti ratio
1 NaBH4/CH2Cl2/ -63 °Cc 3 7a/b, -, -
2 NaBH4/CH2Cl2/ r.t. 3 7a/b, 56, 1:7.5
3 NaBH4/MeOH/ r.t. 1.5 7a/b, 75, 1:10
4 NaBH4/i-PrOH/ r.t. 12 7a/b, 45, 1:427
5 PhMe2SiH, HMPA, 0 °Cd 2 7a/b, 50, 1:3
a
 Yields refer to isolated and purified products; b all spectral data (1H NMR, 
13C NMR, IR, HRMS) are compatible with the proposed structures; c see 
reference 25; (d) see reference 26.
hydroxyl group of anti-cyanide 7b. Then, compound 7b 
was treated with tert-butyldimethylsilyl chloride (TBSCl) 
and imidazole in anhydrous dimethyl formamide (DMF) 
to afford the silylether 18 in 78% yield.
Figure 4. Determining the stereochemical ratio of cyano-ester 7a/b. A. Diastereoisomeric ratio (syn:anti; 1:2) obtained by direct addition of cyanide on the 
double bond of the adduct. Signal centered at 5.08 ppm was atributted to the syn isomer (J 2.8 and 5.1 Hz), while that centered at 4.92 ppm (J 3.5 and 7.8 Hz) 
was atributted to the anti one. In both cases the minor coupling constants are due to the coupling with the hydroxyl hydrogen. B. Diastereoisomeric ratio 
obtained just after ketoester reduction with NaBH4.
A dichloromethane solution of 18 was then treated with 
a solution of diisobutylaluminium hydride (DIBAL-H) 
(3 equiv.), at -78 °C for 3 h to give the lactol 14 in 
91% (Scheme 5). DIBAL-H reduces the ester group 
to the primary alcohol and nitrile to an imine, which 
is quenched at this stage. During the aqueous workup, 
imine is hydrolyzed to the aldehyde, which reacts with 
the alcohol to give lactol 14 (Scheme 5). The NMR 
analysis of lactol 14 was tedious, since the temporary 
appearance of a third stereogenic center excessively 
complicates the spectrum. Thus, 14 was directly treated 
with tetrapropylammonium perruthenate (TPAP) in 
the presence of N-methylmorpholine-N-oxide (NMO) 
and molecular sieve (MS, 4 Å) to afford silylated anti-
butyrolactone 19 in 92%.28
Removal of the protecting group with tetra-n-
butylammonium fluoride (TBAF) in MeOH gave anti-b-
piperonyl-g-butyrolactone 9 in 94% (Scheme 5).
All spectroscopic data are compatible with the proposed 
structure. The anti-b-piperonyl-g-butyrolactone 9 was 
prepared in a highly diastereoselective approach in 36% 
overall yield, in 8 steps starting from piperonal.
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Scheme 5. Diastereoselective preparation of anti-butyrolactone. Reagents and conditions: (a) TBSCl, imidazole, DMF (drops), 18 h, r.t., 78%; (b) DIBAL-H, 
CH2Cl2, -78 °C, 3 h, 91%; (c) TPAP, NMO, MS (4 Å), 1 h, 92%; (d) TBAF, MeOH, 0 °C, 2 h, 95%.
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To demonstrate the feasibility of this strategy we also 
prepared syn-butyrolactone (8), using a similar synthetic 
sequence. To direct the diastereoselectivity towards the 
formation of the syn isomer, the secondary hydroxyl group 
of Morita-Baylis-Hillman adduct should be protected 
before the cyanide addition. The enhanced presence of 
the silyl group alters the course of the Michael addition 
leading to the syn isomer as the major product (Scheme 6).
Initially adduct 16 was silylated to afford the silyl ether 
20 in 95%. Michael addition reaction yielded cyanide-
esters 18a/b as a mixture of diastereoisomers in which 
the syn isomer is the major one (4:1). This stereochemical 
ratio is certainly defined during the protonation of the 
enol intermediate formed after the addition of cyanide 
(Scheme 7). This protonation should likely occur in the 
enol face in opposite to the silyl group. However, the 
preference for this face seems to be not so high. A careful 
analysis of the proposed conformers clearly shows that 
we have a steric enhancement in both faces, although one 
side (opposite to TBDS group) being most accessible 
than other. This observation can explain the moderate 
selectivity attained.
We made several attempts to separate these 
diasteroisomers by column chromatography at this stage, 
however, only slight enrichment of the mixture in favor 
of the syn isomer was realized. DIBAL-H reduction 
afford the lactol, which was immediately oxidized to the 
corresponding silylated lactone in 84% yield over two steps. 
The silyl group was removed to provide syn-hydroxylated 
b-piperonyl-g-butyrolactone (8) in 95%. Unfortunately, 
lactone syn was already contaminated with a small 
amount of the anti isomer (7:1). The syn-butyrolactone 
was prepared in an overall yield of 56% in 7 steps from 
piperonal.
The optimized synthetic sequence was now employed 
for the synthesis of (±)-yatein (11), (±)-podorhizol (12) and 
(±)-epi-podorhizol (13), through a common intermediate.
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To perform the lignan syntheses we have decided to 
use the sequence depicted in Scheme 8. Hydrogenolysis 
of 19b in the presence of hydrogen and palladium on 
carbon at 60 psi provide b-piperonyl-g-butyrolactone 
21, after 4 h, in 92% yield. Alkylation of 21 with the 
3,4,5-trimethoxybenzyl bromide (22)29 in the presence 
of LDA at -78 °C gave (±)-yatein (11) in 80% yield 
(Scheme 8). To synthesize podorhizol and epi-podorhizol 
we simply change the electrophile at the condensation 
step. Instead of bromide we use commercially available 
3,4,5-trimethoxy-benzaldehyde in an aldolic condensation. 
The diastereoisomers (1:1 ratio) were easily separated 
by column chromatography, as previously reported 
(Scheme 6).30 All spectroscopic data for epimeric lignans 
are completely compatible to those available in literature.31
The lignans were prepared in 6 steps from Morita-
Baylis-Hillman adduct 16. (±)-Yatein (11) was prepared 
in 49% overall yield. (±)-Podorhizol (12) and (±)-epi-
podorhizol (13) were prepared both in 6 steps from Morita-
Baylis-Hillman adduct 16 in 24.5 and 24% overall yield, 
respectively. All spectroscopic data are compatible with 
the proposed structures.
Conclusions
In summary we have described an alternative and 
efficient strategy for the synthesis of lignans from Morita-
Baylis-Hillman adduct. This simple and straighforward 
sequence allows the diastereoseletive synthesis of anti 
and syn hydroxylated b-piperonyl-g-butyrolactone in 
good overall yield. As far as we know this is the first 
report concerning the total synthesis of lignans from a 
Morita-Baylis-Hillman adduct. Due to the ease to which 
different Morita-Baylis-Hillman adducts were obtained, 
this approach can be used to furnish lignans of greater 
molecular diversity. Finally, we have demonstrated that 
Morita-Baylis-Hillman adducts can be considered as a 
valuable substrate to prepare lignans.
Experimental 
General
The 1H and 13C NMR spectra were recorded with a 
Varian GEMINI BB at 300 and 75.4 MHz and Bruker 
at 250 and 62.5 MHz, respectively, or on an Inova 
Instrument at 500 and 125 MHz, respectively. The mass 
spectra were recorded using a HP model 5988A GC/MS 
with a High Resolution Autospec/EBE. IR were obtained 
with a Nicolet model Impact 410. Diastereoselectivities 
were determined from GC analysis on a HP6890 with 
flame ionization detector, using a HP-5 capillary (cross 
linked 5% phenyl methyl siloxane, 28 m) column or by 
NMR. Manipulations and reactions were not performed 
under a dry atmosphere or employing dry solvents, 
unless otherwise specified. Purifications and separations 
by column chromatography were performed on silica 
gel, using normal or flash chromatography. Thin-layer 
chromatography (TLC) visualization was achieved by 
spraying with 5% ethanolic phosphomolybdic acid and 
heating. Morita-Baylis-Hillman reactions were sonicated 
in an UNIQUE model GA 1000 ultrasonic bath (1000 W, 
25 kHz). Ice was added occasionally to avoid increasing 
the temperature of the water of the ultrasonic bath, which 
was maintained between 30 and 40 °C. Reagents were 
purchased from Aldrich, Acros or Lancaster, and were used 
without prior purification.
(±)-Methyl 2-[1,3-benzodioxol-5-yl(hydroxy)methyl]prop-
2-enoate (16)
A mixture of piperonal (12 g, 79.9 mmol), methyl 
acrylate (54 mL, 0.6 mol), 1-methyl-3-butylimidazolium 
hexafluorophosphate [bminPF6] (0.23 g, 0.79 mmol) and 
1,4-diazabicyclo[2.2.2]octane (DABCO) (5.83 g, 52 mmol) 
was kept in an ultrasound bath for 20 h. Next, a new portion 
of methyl acrylate was added (54 mL, 0.6 mol) and the 
reaction was kept on the ultrasound for 20 h. This procedure 
was repeated twice to complete 80 h. The reaction medium 
was then evaporated and the acrylate was almost totally 
recuperated. The crude was diluted with dichloromethane 
(100 mL), washed with distilled water (100 mL) and brine 
(50 mL). The organic phase was dried over Na2SO4 and 
the solvent was removed under reduced pressure. The 
residue was purified by silica gel column chromatography 
(hexane:AcOEt, 4:1, v/v) to provide 16.8 g of adduct 16 
in 89% yield, as yellow tinged oil, which crystalise on 
standing. mp 40-42 °C; IR nmax/cm-1 3490, 2954, 2897, 
1703, 1630, 1487, 1438, 1295, 1246, 1037 (film); 1H NMR 
(CDCl3, 300 MHz) d 6.85-6.74 (m, 3H aromatics), 6.32 
(d, 1H, J 0.9 Hz), 5.93 (s, 2H), 5.86 (d, 1H, J 0.9 Hz), 
5.46 (d, 1H, J 5.3 Hz), 3.71 (s, 3H), 3.06 (d, 1H, J 5.3 Hz, 
exchangeable with D2O); 13C NMR (CDCl3, 75.4 MHz) 
d 166.8, 147.8, 147.2, 141.9, 135.3, 120.2, 108.2, 107.2, 
101.1, 72.9, 51.9; HRMS (70 eV, m/z) Calc. for C12H12O5: 
236.06847. Found: 236.0685.
(±)-Methyl 2-[(tert-butyldimethylsilyloxy)(1,3-benzodioxol-
5-yl)methyl]prop-2-enoate (20)
To a solution of 16 (3 g, 12.7 mmol) in dichloromethane 
(100 mL) was added, at 0 °C and under an inert gas 
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atmosphere, Et3N (3.5 mL, 25.5 mmol) and TBSOTf 
(3.5 mL, 16.5 mmol). The resulting solution was stirred 
at room temperature for 1 h. After that, the reaction 
medium was diluted with dichloromethane (100 mL) 
and the organic phase was washed a saturated solution 
of NaHCO3 (200 mL) and distilled water (100 mL). The 
organic phase was dried over anhydrous Na2SO4 and the 
solvent was removed under reduced pressure. The residue 
was purified by flash silica gel column chromatography 
(hexane: AcOEt, 9:1, v/v) to provide 20 (4.35 g), in 98% 
yield, as a viscous oil. IR nmax/cm-1 2954, 2888, 2860, 
2833, 1720, 1634, 1495, 1438, 1246, 1152, 1070, 1041 
(film); 1H NMR (CDCl3, 300 MHz) d 6.85-6.79 (m, 2H 
aromatics), 6.70 (d, 1H, J 8.4 Hz), 6.22 (dd, 1H, J 1.7 and 
1.2 Hz), 6.05 (dd, 1H, J 1.7 and 1.7 Hz), 5.92 (d, 1H, 
J 1.5 Hz), 5.91 (d, 1H, J 1.5 Hz), 5.51 (bs, 1H), 3.67 (s, 
3H), 0.9 (s, 9H), 0.04 (s, 3H), -0,10 (s, 3H); 13C NMR 
(CDCl3, 75.4 MHz) d 166.3, 147.3, 146.7, 136.6, 120.6, 
107.7, 107.4, 100.9, 72.3, 51.6, 25.7, 18.1, -4.9, -5.13; 
HRMS (ESI, m/z) Calc. for C18H26O5Si: 350.15495. 
Found: 294.09234 [M-57]+.
(±)-Methyl 3-(1,3-benzodioxol-5-yl)-2-(cyanomethyl)-3-
hydroxypropanoate (7a/b)
To a solution of 16 (3 g, 12.7 mmol) in a mixture of 
dimethylformamide and water (3:1) was added potassium 
cyanide (2.79 g, 42.8 mmol) and ammonium chloride 
(2.29 g, 42.8 mmol). The resulting mixture was stirred at 
room temperature for 12 h. After that, the medium was 
diluted with distilled water (200 mL) and the aqueous phase 
was extracted twice with ethyl acetate (100 mL each). The 
organic phases were combined and washed with distilled 
water (2 × 100mL) and brine (100 mL). The organic phase 
was then dried over Na2SO4 and the solvent removed under 
reduced pressure. The residue was purified by flash silica 
gel column chromatography (hexane:AcOEt, 7:3, v/v) to 
give 7a/b (2.51 g), in 75% yield, as a viscous tinged yellow 
oil, in a mixture of diastereoisomers (anti:syn; 1.5:1). 
mp 50-52 °C; IR nmax/cm-1 3459, 2958, 2901, 2251, 1736, 
1487, 1434, 1239, 1037 (film); 1H NMR (CDCl3, 300 MHz) 
d 6.85-6.75 (m, 3H aromatics), 5.97 (s, 2H), 5.09 (dd, 1H, 
J 2.9 and 5.1Hz, syn diastereoisomer), 4.90 (dd, 1H, J 3.5 
and 7.7 Hz, anti diastereoisomer), 3.79 (s, 3H), 3.72 (s, 
3H), 3.10-2.92 (m, 2H), 3.08-3.03 (m, 1H), 3.03-3.0 (m, 
1H), 2.82 (dd, 1H, J 9 and 17 Hz, CH2CN, anti), 2.62 (d, 
1H, J 4.4 Hz, CH2CN, syn), 2.56 (d, 1H, J 4.9 Hz, CH2CN, 
syn), 2.42 (dd, 1H, J 8 and 17 Hz, CH2CN, anti); 13C NMR 
(CDCl3, 75.4 MHz) d 171.8, 171.5, 148.2, 147.9, 147.6, 
133.9, 133.3, 120, 119.9, 118, 117.1, 108.4, 108.3, 106.3, 
106.1, 101.3, 101.2, 73.7, 72.6, 52.7, 52.6, 49.4, 48.8, 16.9, 
14.9; HRMS (ESI, m/z) Calc. for C13H13NO5: 263.07937. 
Found: 263.07892.
(±)-Methyl 3-(tert-butyldimethyl silyloxy)-3-(1,3-
benzodioxol-5-yl)-2-(cyanomethyl)propanoate (18a/b)
To a solution of 20 (4.45 g, 12.7 mmol) in a mixture of 
dimethylformamide and water (4:1) was added potassium 
cyanide (2.79 g, 42.8 mmol) and ammonium chloride 
(2.29 g, 42.8 mmol). The resulting mixture was stirred at 
room temperature for 12 h. After that, the medium was 
diluted with distilled water (200 mL) and the aqueous 
phase was extracted twice with ethyl acetate (100 mL 
each). The combined organic phases were washed with 
distilled water (2 × 100 mL) and brine (100 mL). After 
removal of the solvent under reduced pressure, the residue 
was purified by flash silica gel column chromatography 
(hexane:AcOEt, 4:1, v/v) to afford 3.69 g of a colorless 
viscous oil, in 83% yield, as a mixture of diastereoisomer 
(anti:syn; 1:4). IR nmax/cm-1 2954, 2924, 2883, 2854, 2241, 
1735, 1444, 1492, 1248, 1076, 1040 (film); 1H NMR 
(CDCl3, 300 MHz) d 6.90-6.60 (m, 3H aromatics), 5.97 
(bs, 2H), 5.10 (d, 1H, J 4.3 Hz, diastereoisomer syn), 4.82 
(d, 1H, J 7.6 Hz, diastereoisomer anti), 3.78 (s, 3H, anti), 
3.76 (s, 3H, syn), 3.05-2.70 (m, 2H), 2.50-2.36 (m, 1H), 
0.97 (s, 9H, syn), 0.96 (s, 9H, anti), 0.01 (s, 3H, anti), 
0.0 (s, 3H, syn), -0.02 (s, 3H, anti), -0.25 (s, 3H, syn); 
13C NMR (CDCl3, 75.4 MHz) diastereoisomer syn: d 170.7, 
147.7, 147.3, 133.9, 119.3, 118.5, 108.1, 106.3, 73.9, 52.3, 
51.4, 25.6, 17.9, 14.2, -4.7, -5.4; diastereoisomer anti: 
d 171.3, 148, 147.8, 133.8, 120.9, 117.6, 108.1, 106.5, 74.8, 
52.3, 51, 25.5, 17.9, -4.7, -5.5; HRMS (EI, m/z) Calc. for 
C19H27NO5Si: 377.16585. Found: 377.16319.
(±)-Methyl 3-(1,3-benzodioxol-5-yl)-2-(cyanomethyl)-3-
oxopropanoate (15)
To a solution of 7a/b (0.5 g, 1.9 mmol) in acetone 
(50 mL) was added drop by drop, at 0 °C, a freshly 
prepared solution of the Jones reagent24 (5 mL). The 
reaction was monitored by TLC until the complete 
disappearance of the starting material. If necessary a 
tiny amount of the Jones reagent was added again. After 
the completion, an excess of isopropanol was added and 
the mixture was stirred just to become green. Then, the 
reaction was diluted with ethyl acetate (150 mL) and 
the organic phase was washed with water (2 × 150 mL) 
and brine (150 mL). The organic phase was dried over 
Na2SO4 and removed under reduced pressure. The residue 
was purified by flash silica gel column chromatography 
(hexane:AcOEt, 1:1, v/v) to give 15 in 94% yield, as a 
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tinged yellow viscous oil. IR nmax/cm-1 2970, 2953, 2238, 
1740, 1679, 1437, 1254, 1037 (film); 1H NMR (CDCl3, 
500 MHz) d 7.65 (d, 1H, J 3 Hz), 7.48 (s, 1H), 6.90 (d, 
1H, J 3 Hz), 6.05 (s, 2H), 4.65 (apt, 1H, J 12 Hz), 3.75 (s, 
3H), 3.18-2.95 (m, 2H); 13C NMR (CDCl3, 75 MHz) d 189, 
167.3, 153, 148.6, 129.5, 126, 117.3, 108.5, 108.1, 102.2, 
53.4, 49.5, 16.9; HRMS (EI, m/z) Calc. for C13H11NO5: 
261.06372. Found: 261.063351.
anti-(±)-Methyl 3-(1,3-benzodioxol-5-yl)-2-(cyanomethyl)-
3-hydroxypropanoate (7b)
To a stirred solution of ketoester 15 (0.173 g, 
0.67 mmol) in methanol (3 mL) was added, at 0 °C, sodium 
borohydrate (0.025 g, 0.66 mmol). The reaction was stirred 
at room temperature for 90 min. The solvent was then 
removed under reduced pressure and the residue was diluted 
with ethyl acetate (30 mL). The organic phase was washed 
with distilled water (2 × 30 mL) and a saturated solution of 
ammonium chloride (30 mL). The organic phase was then 
filtered over a pad of Celite® and dried over Na2SO4. The 
solvent was removed under reduced pressure. The residue 
was purified by flash silica gel column chromatography 
to provide 7b, in 75% yield, as a colorless oil and high 
diastereoisomeric purity (anti:syn;10:1). IR nmax/cm-1 3462, 
2958, 2916, 2247, 1736, 1602, 1504, 1489 (film); 1H NMR 
(CDCl3, 500 MHz) d 6.87 (m, 3H), 6.0 (s, 2H), 4.95 (d, 
1H, J 7.5 Hz), 3.80 (s, 3H), 3.08-3.03 (m, 1H), 2.62 (dd, 
1H, J 9 and 17 Hz), 2.42 (dd, 1H, J 8 and 17 Hz); 13C NMR 
(CDCl3, 75 MHz) d 171.3, 148.2, 147.9, 133.2, 120, 117, 
108.4, 108.1, 106.3, 101.3, 52.8, 48.9, 17.1; HRMS (EI, 
m/z) Calc. for C13H13NO5: 263.07937. Found: 263.07921.
anti-(±)-Methyl 3-(tert-butyldimethyl silyloxy)-3-(1,3-
benzodioxol-5-yl)-2-(cyanomethyl)propanoate (18b)
To a mixture of cyano-ester 7b (0.27 g, 1 mmol), tert-
butyldimethylsilyl chloride (0.2 g, 1.3 mmol) and imidazole 
(0.17 g, 2.5 mmol), under an inert gas atmosphere, was 
added 2 drops of anhydrous DMF. The resulting mixture 
was vigorously stirred for 18 h, at room temperature. After 
that, the reaction was diluted with ethyl acetate (25 mL). The 
organic phase was washed with distilled water (25 mL) and 
brine (25 mL). After solvent removal, the residue was purified 
by flash silica gel column chromatography (hexane:AcOEt, 
70:30) to provide 18b, in 78% yield, as a colorless viscous 
oil. IR nmax/cm-1 2949, 2925, 2888, 2851, 2251, 1740, 1491, 
1442, 1241, 1172, 1086, 1033 (film); 1H NMR (CDCl3, 
500 MHz) d 6.80-6.60 (m, 3H), 5.96 (s, 2H), 4.85 (d, 1H, 
J 7.6 Hz), 3.76 (s, 3H), 2.98 (m, 1H), 2.33 (d, 2H, J 6.4 Hz), 
0.92 (s, 9H), 0.02 (s, 3H), -0.01 (s, 3H); 13C NMR (CDCl3, 
75 MHz) d 171.6, 148.2, 147.9, 133.2, 120, 117.4, 108.4, 
106.3, 101.3, 73.7, 52.8, 48.9, 17.1; HRMS (EI, m/z) Calc. 
for C19H27NO5Si: 377.16585. Found: 377.16319.
anti-(±)-4-[1,3-Benzodioxol-5-yl(tert-butyldimethyl 
silyloxy)methyl]tetrahydrofuran-2-ol (14b)
To a solution of cyano-ester 18b (0.18 g, 0.48 mmol) 
in anhydrous dichloromethane (15 mL), at –78 °C, in an 
inert gas atmosphere, was added diisobutyl aluminum 
hydride (DIBAL-H, 1 mol L-1 solution in toluene, 
1.56 mL, 1.56 mmol). The resulting mixture was stirred 
at -78 °C after 3 h. Then, a saturated solution of sodium 
acetate was added at -78 °C and the reaction was warmed 
at room temperature. After that, the reaction was dropped 
over a mixture of ethyl acetate (15 mL) and saturated 
solution of ammonium chloride (5 mL) and stirred after 
1 h. The resulting gel was filtered over a pad of Celite®. 
The cake was washed with an additional amount of ethyl 
acetate (25 mL). The combined organic phases were 
dried over Na2SO4 and the solvent was removed under 
reduced pressure. The residue was purified by flash silica 
gel column chromatography (hexane:AcOEt, 7:3, v/v) to 
afford 0.155 g of 14b, in 91% yield, as a viscous light 
yellow oil. IR nmax/cm-1 3411, 2953, 2925, 2884, 2855, 
1491, 1437, 1237, 1074, 1045 (film); 1H NMR (CDCl3, 
250 MHz) d 6.90-6.60 (m, 3H), 5.95 (s, 2H), 5.60-5.30 
(m, 1H), 4.70-4.30 (m, 1H), 4.20-3.40 (m, 2H), 4.15 (bs, 
1H), 3.05 (bs, 1H), 2.90-2.40 (m, 1H), 2.20-1.40 (m, 2H), 
0.92-0.82 (2s, 2 × 9H), 0.10-0.0 (2s, 2 × 3H), -0.12 - 
-0.26 (2s, 2 × 3H); 13C NMR (CDCl3, 62.5 MHz) d 147.6, 
147.5, 146.8, 146.7, 138, 137.9, 119.8, 119.6, 107.7, 
107.6, 106.7, 106.6, 100.9, 98.7, 98.6, 77.4, 77.2, 70.3, 
69.6, 47.4, 46.2, 25.7, 25.6, 18.03, 18, -4.48, -5.1, -5.2; 
HRMS (ESI, m/z) Calc. for C18H28O5Si + Na: 375.1604 
[M + Na]+. Found: 375.1557 [M + Na]+.
anti-(±)-4-[1,3-Benzodioxol-5-yl(tert-butyldimethyl 
silyloxy)methyl]dihydrofuran-2(3H)-one (19b)
To a solution of lactol 14b (0.18 g, 0.52 mmol) in 
anhydrous dichloromethane (20 mL), at room temperature 
under an inert gas atmosphere, was added molecular 
sieves (4 Å, 0.27 g), N-Methyl morpholine (NMO, 
0.12 g, 1.04 mmol) and tetrapropylammonium ruthenate 
(TPAP, 0.0184 g, 0.04 mmol). The resulting mixture was 
stirred after 1 h. Then the crude was filtered over a pad of 
Celite® and the solvent removed under reduced pressure. 
The residue was purified by flash silica gel column 
chromatography to afford 0.165 g of 19b, in 92% yield, 
as colorless viscous oil. IR nmax/cm-1 2953, 2929, 2892, 
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2851, 1777, 1491, 1437, 1241, 1172, 1078, 1033, 1008 
(film); 1H NMR (CDCl3, 250 MHz) d 6.80-6.65 (m, 3H), 
5.95 (s, 2H), 4.48 (d, 1H, J 6.8 Hz), 4.28 (m, 2H), 2.76 
(m, 1H), 2.31 (m, 1H), 0.87 (s, 9H), 0.03 (s, 3H), -0.22 (s, 
3H); 13C NMR (CDCl3, 62.5 MHz) d 176.7, 147.8, 147.2, 
136.1, 119.4, 108, 106.3, 101, 75.5, 70, 44.1, 31.2, 25.7, 
17.9, -4.53, -5.26; HRMS (ESI, m/z) Calc. for C18H26O5Si: 
351.1648 [M + H]+. Found: 351.1628 [M + H]+.
anti-(±)-4-[1,3-Benzodioxol-5-yl(hydroxy)methyl]
dihydrofuran-2(3H)-one (7b)
To a solution of 19b (0.1 g, 0. 38 mmol) in methanol 
(5 mL) was added, at 0 °C and in an inert gas atmosphere, 
tetrabutylammonium fluoride (solution 1 mol L-1 in THF, 
0.45 mL, 0.45 mmol). The resulting mixture was stirred 
at the same temperature after 2 h. Then, the solvent was 
removed under reduced pressure and the residue was diluted 
with ethyl acetate (25 mL). The organic phase was washed 
with distilled water (2 × 10 mL) and brine (10 mL) and dried 
over anhydrous Na2SO4. After solvent removal, the residue 
was purified by flash silica gel column chromatography 
to give 7b as colorless viscous oil, in 95% yield. 
IR nmax/cm-1 3429, 2900, 1771, 1492, 1444, 1248, 1040 
(film); 1H NMR (CDCl3, 250 MHz) d 6.90-6.70 (m, 3H), 
5.95 (s, 2H), 4.38 (d, 1H, J 8.0 Hz), 4.16 (dd, 1H, J 7.8 
and 9.3 Hz), 4.03 (dd, 1H, J 6.4 and 9.3 Hz), 2.20-2.40 
(m, 2H); 13C NMR (CDCl3, 62.5 MHz) d 177.4, 148, 
147.5, 135.8, 119.6, 108.2, 106.2, 101.2, 74.4, 69.9, 42.4, 
30.7; HRMS (EI, m/z) Calc. for C12H12O5: 236.06847. 
Found: 236.06831.
(±)-4-(1,3-Benzodioxol-5-ylmethyl)dihydrofuran-2(3H)-
one (21)
To a solution of 18a/b (0.55 g, 1.57 mmol) in methanol 
(50 mL) was added 5% Pd/C (0.034 g, 0.16 mmol) 
and two drops of concentrated hydrochloric acid. The 
resulting mixture was placed in a hydrogenation bottle, 
which was maintained in a shaker equipment, under 
hydrogen pressure (60 psi, 4 atm) after 4 h. Then, the 
mixture was neutralized with solid sodium bicarbonate 
and filtered over a pad of Celite®. The cake was washed 
with ethyl acetate (10 mL). The combined organic 
phases were removed and the crude was redissolved in 
ethyl acetate (50 mL). The organic phase was washed 
with distilled water (25 mL), brine (25 mL) and finally 
dried over anhydrous Na2SO4. The solvent was removed 
under reduced pressure. The residue was purified by 
flash silica gel column chromatography to afford 21, as a 
yellow tinged fluid oil, in 92% yield. IR nmax/cm-1 2909, 
1769, 1487, 1438, 1248, 1037 (film); 1H NMR (CDCl3, 
300 MHz) d 6.75 (d, 1H, J 7.8 Hz), 6.63 (d, 1H, J 1.7 Hz), 
6.59 (dd, J 1.7 and 7.8 Hz), 5.94 (s, 2H), 4.33 (dd, 1H, 
J 6.8 and 9.2 Hz), 4.02 (dd, 1H, J 6.0 and 9.2 Hz), 2.80 (m, 
1H), 2.69 (m, 2H), 2.60 (dd, 1H, J 8.0 and 17 Hz), 2.27 
(dd, 1H, J 6.8 and 17 Hz); 13C NMR (CDCl3, 75.4 MHz) 
d 176.5, 147.8, 146.2, 131.7, 121.5, 108.7, 108.3, 100.9, 
72.5, 38.7, 37.3, 34.2; HRMS (EI, m/z) Calc. for C12H12O4: 
220.07356. Found: 220.07341.
Preparation of (±)-yatein (11)
To a solution of 21 (0.12 g, 0.54 mmol) in anhydrous 
THF (5 mL), at –78 °C and in an inert gas atmosphere, was 
added a freshly prepared 1mol L-1 LDA solution (0.6 mL, 
0.6 mmol). The temperature was raised until the room one 
and then the system was cooled again to -78 °C and stirred 
for 30 min. After that, a solution of 5-(bromomethyl)-1,2,3-
trimethoxybenzene (0.71 g, 2.72 mmol) in anhydrous THF 
(0.5 mL) was added. The final mixture was stirred after 6 h. 
Then, a saturated solution of ammonium chloride (1 mL) 
was added and the reaction was extracted with ethyl acetate 
(30 mL). The organic phase was washed with distilled water 
(20 mL), brine (20 mL) and dried over anhydrous Na2SO4. 
After solvent removal, the residue was purified by flash 
silica gel column chromatography (hexane:AcOEt, 8:2, 
v/v) to provide (±)-yatein (11) as a fluid tinged yellow oil, 
in 80% yield. IR nmax/cm-1 2994, 2941, 2839, 1768, 1593, 
1507, 1486, 1458, 1417, 1331, 1245, 1127, 1037, 1017 
(film); 1H NMR (CDCl3, 300 MHz) d 6.68 (d, 1H, J 6.9 Hz), 
6.47 (dd, 1H, J 1.6 and 6.9 Hz), 6.44 (bs, 1H), 6.35 (s, 2H), 
5.92 (m, 2H), 4.18 (dd, 1H, J 7.1 and 9.3 Hz), 3.90-3.84 
(m, 1H), 3.84 (s, 3H), 3.82 (s, 6H), 2.95-2.85 (m, 2H), 
2.70-2.40 (m, 4H); 13C NMR (CDCl3, 62.5 MHz) d 178.1, 
153, 147.7, 146.2, 136.7, 133.1, 131.3, 121.4, 108.6, 108.2, 
106.2, 101, 71.4, 60.9, 56.1, 46.5, 41, 38.4, 35.3; HRMS 
(EI, m/z) Calc. for C22H24O7: 400.15220. Found: 400.15198.
Preparation of (±)-podorhizol (12) and (±)-epi-podorhizol 
(13)
To a solution of 21 (0.1 g, 0.44 mmol) in anhydrous 
THF (5 mL), at –78 °C and under an inert gas atmosphere, 
was added a solution of freshly prepared lithium 
diisopropylamine (LDA, 0.2 mol L-1, 0.26 mL, 0.42 mmol). 
The resulting solution was allowed to warm to 0 °C 
during 30 min. After the solution was cooled again to 
-78 °C and stirred after 30 min. Then a solution of 
3,4,5-trimethoxybenzaldehyde (0.08 g, 0.44 mmol) in 
anhydrous THF (2 mL) was added. The resulting solution 
was stirred after 1 h, at -78 °C. Then the reaction was 
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quenched with a saturated solution of ammonium chloride 
(10 mL) and warmed to the room temperature. The medium 
was extracted with ethyl acetate (30 mL) and the organic 
phase was washed with distilled water (2 × 10 mL) and 
dried over anhydrous Na2SO4. The isomers were separated 
by flash silica gel column chromatography (CH2Cl2:MeOH, 
98:2, v/v) to afford 12 and 13 in a combined yield of 80%. 
(±)-Podorhizol (12): Yield: 41%; mp 123-125 °C 
(124-126 °C)29; IR nmax/cm-1 3500, 1762, 1590, 1490 
(KBr); 1H NMR (300 MHz, CDCl3) d 6.47 (s, 2H), 6.59 
(d, 1H, J 7.7 Hz), 6.30 (dd, 1H, J 7.8 and 1.5 Hz), 6.22 (d, 
1H, J 1.5 Hz), 5.92 (dd, 2H, J 1.4 and 1.4 Hz), 5.25 (d, lH, 
J 2.9 Hz), 4.39 (dd, lH, J 8.7 and 8.0 Hz), 3.97 (dd, lH, 
J 8.7 and 8.9 Hz), 3.83 (s, 3H, 3.82 (s, 6H), ca. 2.80 (m, 
lH), 2.62 (dd, lH, J 6.1 and 2.9 Hz), 2.47 (dd, lH, J 13.7 
and 7.7 Hz), 2.25 (dd, lH, J 3.7 and 8.1Hz); 13C NMR 
(75.4 MHz, CDCl3) d 178.3, 153.4 (2 × C), 147.9, 146.3, 
137.6, 136.8, 131.5, 121.5, 108.6, 107.9, 102.6, 101.1, 72.8, 
72.1, 60.8, 56.2 (2 × OCH3), 52.8, 39.4, 36.4
(±)-epi-Podorhizol (13): Yield: 39%; mp 132-133 °C 
(133-134 °C)29; IR29c nmax/cm-1 3500, 3010, 2780, 1760, 
1600, 1510, 1490, 1230, 1120, 925 (film-CHCl3); 1H NMR 
(300 MHz, CDCl3) d 6.66 (d, 1H, J 8.2 Hz), 6.65(s, 2H), 
6.34 (dd, 1H, J 8.21 and 7 Hz), 6.33(d, 1H, J 1.7Hz), 5.92 
(dd, 2H, J 1.4 and 1.4 Hz,-OCH2O-) ,4.79 (d, 1H, J 7.9 Hz), 
4.18 (dd, 1 H, J 9.3 and 7.8 Hz), 3.92 (dd, 1H, J 9.3 and 
8.4 Hz), 3.88 (s, 6H), 3.83 (s, 3H), 2.62 (dd, 1H, J 9.1 and 
7.8 Hz), ca. 2.50 (m, lH), 2.20 (dd, 1H, J 13.8 and 8.9 Hz), 
2.12 (dd, 1H, J 13.7 and 5.4Hz); 13C NMR (125 MHz, 
CDCl3) d 178.7, 153.8 (2 × C), 148.1, 146.6, 138.7, 135.8, 
131.6, 121.5, 108.7, 108.4, 104.1 (2 × C), 101.1, 74.7, 72, 
61, 56 (2 × C), 51.7, 38.9, 38.3.
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